Covaxin-maker Bharat Biotech early on Saturday confirmed that the coronavirus vaccine shows 77.8% efficacy against the infection. The comp...
Covaxin-maker Bharat Biotech early on Saturday confirmed that the coronavirus vaccine shows 77.8% efficacy against the infection. The company published the pre-print data of the third phase of the vaccine trials in the medical journal medRxiv.
On June 23, reports citing unidentified officials had suggested that a Subject Expert Committee of the Central Drugs Standard Control Organisation had accepted trial data of the vaccine. This came after Bharat Biotech submitted the data to the Drug Controller General of India.
In the data published on Saturday, Bharat Biotech claimed that Covaxin shows 65.2% efficacy against the Delta variant of coronavirus. The strain, first detected in India, has been classified as a “variant of concern” by the World Health Organization. It is likely to become the dominant strain of the virus in the coming months, the health body warned recently.
COVAXIN® Proven SAFE in India's Largest Efficacy Trial. Final Phase-3 Pre-Print Data Published on https://t.co/JJh9n3aB6V pic.twitter.com/AhnEg56vFN
— BharatBiotech (@BharatBiotech) July 2, 2021
The indigenously developed Covaxin shot was granted emergency use authorisation in India in January though data of phase 3 trials were not available at that time. The company had then said it would submit efficacy results by March. On June 9, it said that the data will be made public in July.
In April, an interim analysis of...
